Biopharma is going public again. That is the unmistakable trend throughout the year so far – indeed it has been clear since the spring of 2022. And the third quarter has seen the most cash raised by floating biotech companies since the end of 2021, totalling $1.3bn.
Key Takeaways
- Eight biopharma IPOs raised a total of $1.3bn in Q3 2023
This is a rosy picture until you look at how these companies have done on the stock markets since their...